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Abstract
Background: Aggrecan degradation is the hallmark of cartilage degeneration in osteoarthritis (OA), though it is
unclear whether a common proteolytic process occurs in all individuals.
Methods: Aggrecan degradation in articular cartilage from the knees of 33 individuals with OA, who were
undergoing joint replacement surgery, was studied by immunoblotting of tissue extracts.
Results: Matrix metalloproteinases (MMPs) and aggrecanases are the major proteases involved in aggrecan
degradation within the cartilage, though the proportion of aggrecan cleavage attributable to MMPs or
aggrecanases was variable between individuals. However, aggrecanases were more associated with the increase in
aggrecan loss associated with OA than MMPs. While the extent of aggrecan cleavage was highly variable between
individuals, it was greatest in areas of cartilage adjacent to sites of cartilage erosion compared to sites more remote
within the same joint. Analysis of link protein shows that in some individuals additional proteolytic mechanisms
must also be involved to some extent.
Conclusions: The present studies indicate that there is no one protease, or a fixed combination of proteases,
responsible for cartilage degradation in OA. Thus, rather than targeting the individual proteases for OA therapy,
directing research to techniques that control global protease generation may be more productive.
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Background
Aggrecan, the major proteoglycan of articular cartilage,
is responsible for the ability of the tissue to withstand
the compressive loads that it encounters throughout life.
This ability is intimately associated with the structure of
aggrecan, in particular its high degree of substitution
with sulfated glycosaminoglycan chains and its ability to
form large molecular aggregates in association with hya-
luronan (HA) [1]. The aggrecan core protein can be
divided into discrete structural and functional regions
(Fig. 1). At its amino terminus there are two globular re-
gions (G1 and G2) that are separated by a short inter-
globular domain (IGD). The G2 region is followed by
the glycosaminoglycan-attachment region, which con-
sists of a keratan sulfate (KS)-rich domain followed by
two chondroitin sulfate-rich domains (CS1 and CS2). At
the carboxy terminus is a third globular region (G3) [2].
The G1 region is responsible for the interaction of
aggrecan with HA, so preventing free diffusion of the
molecule within the tissue. This interaction is stabilized
by the presence of a link protein (LP) that non-
covalently interacts with both the aggrecan and HA [3].
The KS and CS chains provide the osmotic properties
responsible for retaining water under compressive load,
so preventing tissue damage [4].
The tissue content and structure of aggrecan does not
remain constant throughout life, and its functional ability
declines with age [5]. The major detrimental changes are a
decrease in aggrecan abundance and a truncation of its
core protein. Core protein truncation is due to proteolysis,
with each cleavage producing one fragment that remains
bound to HA and one that is free. The former fragments
are retained within the tissue, whereas the latter are lost
by diffusion into the synovial fluid. When cleavage occurs
within the IGD or glycosaminoglycan-attachment region,
the net result is a decrease in the anionic charge of the
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aggrecan molecule and a decreased ability to resist com-
pression. Any process associated with increased proteoly-
sis will result in more rapid and extensive aggrecan
degradation and loss, weakening the cartilage and
ultimately causing tissue erosion [1].
Since, the interglobular domain and the
glycosaminoglycan-attachment region of the aggrecan
core protein are thought to exist as extended polypep-
tides [6], they are particularly susceptible to proteolytic
attack. In vitro studies of aggrecan degradation have
documented cleavage by a diverse variety of proteolytic
enzymes. The in vivo situation, however, is dependent
on the availability of proteases in the cartilage extracellu-
lar matrix. Determination of the amino acid sequence of
the termini of aggrecan cleavage products has allowed
the production of anti-neo-epitope antibodies specific
for the detection of these products in vivo, allowing their
characterization in articular cartilage extracts and pro-
viding direct evidence for the action of specific proteases
[7]. Although a role for the cysteine protease, calpain
[8], and the serine protease, HTRA1 [9], has been dem-
onstrated in human articular cartilage, two families of
metalloproteases and have been implicated as the major
contributors to aggrecan degradation in vivo [10]. Mem-
bers of the matrix metalloproteinase (MMP) family, in
particular stromelysin (MMP3), and MMP13 are pro-
duced as proenzymes under inflammatory conditions.
Following activation by proteolytic removal of their pro-
peptides, these enzymes cleave aggrecan at sites in the
IGD and the CS1/CS2 region. Two members of the
ADAMTS (a disintegrin and metalloprotease with
thrombospondin motifs) family of metalloproteases,
ADAMTS4 and ADAMTS5 which are collectively
known as aggrecanases, are also potent aggrecan de-
grading enzymes [11]. Both of these multidomain
enzymes cleave the aggrecan core protein at specific
sites in the IGD and the CS2 region. ADAMTS5 has
an especially high activity on aggrecan due to the
high affinity of its non-catalytic domains for glycos-
aminoglycan chains [12, 13].
Indirect evidence for the action of proteases in the
cleavage of aggrecan has been obtained previously from
the characterization of fragments released into the syn-
ovial fluid [14–16]. This approach assumes uniform re-
tention of these components in this compartment. The
purpose of the current work was to study aggrecan pro-
teolysis within the cartilage from patients with OA, in
order to determine how the type and extent of proteoly-
sis varies between individuals.
Methods
Source of reagents
Unless otherwise stated, all chemical reagents used in
this study were purchased from Sigma.
Source of OA cartilage
Articular cartilage was obtained from the femoral con-
dyles of patients undergoing total knee replacement
(Table 1). Sample collection and analysis protocols (IRB
Review Number A03-M26-11A) were approved by the
McGill University Institutional Review Board, and in-
formed consent was obtained from each individual. At
the time of surgery, all individuals were classified as
grade 3-4 based on the Kellgren and Lawrence radio-
graphic scoring system for knee OA [17].
Proteoglycan extraction
About 25–30 mg cartilage was obtained from three
sites for each femoral condyle: adjacent to the lesion
(0–3 mm), remote from the lesion (>6 mm), and
from the area midway between the lesion and the re-
mote site (3–6 mm). The cartilage was divided into
small pieces and extracted with 20 volumes (v/w)
4 M guanidinium chloride, 100 mM sodium acetate,
pH 6.0, containing 1 mM EDTA and a protease in-
hibitor cocktail (Roche Diagnostics) at 4 °C for 48 h.
The extract was recovered by centrifugation and
stored at −20 °C.
Enzyme digestion
Proteoglycan/protein was recovered from the guanidine
extracts by precipitation with 9 volumes (v/v) ethanol
overnight at −20 °C. The precipitate was recovered by
centrifugation and washed two times with 70 % ethanol
before drying. The dry pellet was dissolved in 50 mM so-
dium acetate, pH 6.0, and digested with 0.2 mU/ml kera-
tanase II (Seikagaku) overnight at 37 °C. To adjust the
pH, one tenth volume of 1 M Tris HCl /1 M sodium
acetate, pH 7.3, was then added and the sample digested
Fig. 1 Schematic representation of the structure of aggrecan.
Aggrecan is depicted in association with hyaluronan (HA) and link
protein (LP) as part of a proteoglycan aggregate. The globular
regions of the aggrecan core protein are indicated (G1, G2 and G3)
together with the regions of the core protein substituted with
keratan sulfate (KS) or chondroitin sulfate (CS1 and CS2) chains. The
location of cleavage sites along the core protein for MMPs (M) and
aggrecanases (A) are indicated at the bottom of the figure
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with 10 mU/ml chondroitinase ABC (Seikagaku) at 37 °
C for 6 h.
SDS PAGE and immunoblotting
The keratanase/chondroitinase-digested proteoglycan
was analyzed on NuPAGE 3–8% Tris-acetate mini gels
(Invitrogen) under reducing conditions. Electrophoresis
was conducted at 180 V for 1 h, and the proteins then
transferred to nitrocellulose membranes (Bio-Rad) by
electroblotting at 33 V for 1.5 h. Membranes were
probed with rabbit anti-peptide antibodies recognizing
the G1, G2, G3 [18, 19] and CS1 [20] regions of aggre-
can, or mouse monoclonal antibody 8A4 recognizing
link protein [21]. Bound antibody was detected by
exposure to a biotinylated anti-rabbit or anti-mouse
IgG antibody (Amersham), followed by incubation
with Streptavidin-biotinylated horseradish peroxidase
(Amersham), and then ECL western blotting detection
reagents (Amersham) to visualize reactive bands. The
pixel intensity of bands corresponding to free G1 re-
gions generated by aggrecanase or MMP action was
quantitated by densitometry and reported to three
significant figures (Table 2). The ratio of G1 compo-
nents generated by aggrecanases and MMPs was
calculated.
Proteoglycan assay
Proteoglycan recovered by ethanol precipitation and dis-
solved in the keratanase buffer was assayed for chondro-
itin sulfate content by the dimethylmethylene blue
(DMMB) colorimetric assay using chondroitin 6-sulfate
(Sigma) as a standard (12.5 μg/ml to 200 μg/ml) [22].
20 μl of the proteoglycan sample was combined with
180 μl of DMMB solution (46 mM DMMB (Aldrich),
40 mM glycine, and 40 mM NaCl, pH 3.0) in a 96-well
plate, and the absorbance at 530 nm was monitored.
Reduction and alkylation
Dithiothreitol (5 mM final concentration) was added to
100 μl samples of the guanidine extracts and incubated
at 37 °C for 4 h. Iodoacetamide (15 mM final concentra-
tion) was then added and incubation continued over-
night at room temperature. Samples were then ethanol
precipitated as described above and redissolved in
50 mM Tris, pH 7.5.
Protease digestion
Purified human neonatal aggrecan (4 mg/ml in water)
[5] and ethanol-precipitated guanidine extracts were
digested with trypsin (10 μg/ml), ADAMTS5 (2 nM)
[23] or MMP3 (2 μg/ml; Abcam). Digestion was per-
formed overnight at 37 °C in 50 mM Tris, pH 7.5,
containing 1 mM or 5 mM CaCl2 (for trypsin or metal-
loproteases, respectively). The trypsin digestion was ter-
minated by the addition of phenylmethylsulfonylfluoride
(PMSF, 1 mM final concentration).
Agarose gel electrophoresis
Reduced and alkylated proteoglycans were analyzed by
electrophoresis on 1.2 % agarose gels [24] for 1 h at
90 V. Proteoglycan (8 μg chondroitin sulfate) was used
per well. After electrophoresis, the gel was stained for
Table 1 Details of patients recruited for study
Patient ID Age Gender Condition† Duration (yrs)a
1 73 F OA 12
2 69 F OA 15
3 74 M OA 2
4 71 F OA 3
5 68 F OA 4
6 61 F OA 1
7 72 F OA 3
8 75 F OA 8
9 66 F OA 1.5
10 59 F OA 5
11 51 M Post-traumatic OA 6
12 89 M OA 4
13 78 M OA 1
14 57 F AVN, secondary OA 8
15 73 F OA 3
16 59 M OA 6
17 87 F OA 1.5
18 89 F OA 7
19 77 M OA 1.5
20 77 F OA 4
21 78 M OA 5
22 71 F OA 3
23 71 M OA 1.5
24 46 F AVN, secondary OA 4
25 50 F RA 5.5
26 74 M OA 1.5
27 69 M OA 25
28 83 F OA 3
29 89 F OA 11
30 72 F OA second knee 13
31 80 F OA 20
32 77 M OA 5
33 71 F OA 11
34 95 F OA 3
†OA osteoarthritis, RA rheumatoid arthritis, AVN avascular necrosis
aDuration is the time in years between first report of disease symptoms and
surgery, for each patient
Mort et al. BMC Musculoskeletal Disorders  (2016) 17:89 Page 3 of 10
1 h using 0.02 % Toluidine Blue and then destained with
3 % acetic acid. In addition, trypsin digests of aggrecan
were transferred to a cetylpyridinium chloride-treated
nitrocellulose membrane by capillary transfer after
electrophoresis [25]. Membranes were probed with an
anti-CS1-peptide antibody raised in rabbits against an
ovalbumin conjugate of the peptide GRIEWPSTPTV-
GELGC (Uniprot entry P16112, residues 924–936 -
italicized residues were added to block the antigenic
sequence and to provide a thiol group for coupling to
ovalbumin) [20].
Genomic DNA isolation and sequencing
Genomic DNA was isolated following proteolytic
solubilization of cartilage. 50 mg cartilage was digested
with 0.5 mg proteinase K in 50 mM Tris HCl, 5 mM
EDTA, pH 8.0 at 55 °C for 48 h, and genomic DNA was
recovered by precipitation with one volume of isopropa-
nol. The region of the aggrecan gene encompassing the
location encoding the epitope recognized by the anti-
CS1 antibody was amplified by PCR using the primers
GTGGTGACTTCACAGGCAGT and GCCCACTGAG
GTCTCCTACT. PCR products were then sequenced at
the McGill University Genome Quebec core facility.
Histology and immunohistochemistry
Full thickness cartilage was fixed in periodate-lysine-
paraformaldehyde [26] for 4 h at room temperature,
followed by overnight at 4 °C, and then embedded in a
mixture of 20 % sucrose/OCT compound (Tissue-Tek).
Cryosections were cut at 8 μm and stored at −20 °C. For
histology, sections were stained with Safranin O/ Fast
green. For immunohistochemistry, sections were treated
with 4 % formaldehyde for 10 min, then with chondroiti-
nase ABC (0.25 mU/ml) in the presence of protease in-
hibitors (PMSF, 1 mM; iodoacetamide, 1 mM; EDTA,
1 mM; and pepstatin A, 10 μg/ml) for 1 h at 37 °C. After
treating sections with 0.3 % H2O2/methanol for 30 min
at room temperature, they were exposed to rabbit anti-
peptide antibodies (anti-G1, anti-G1 MMP [27] and
anti-G1 AGG [28], all diluted 1:200). Bound antibody
was identified using the Vectastain ABC kit (Vector
Laboratories), and visualized with diamino benzaldehyde
substrate. Sections were then counterstained with
hematoxylin. Between each step in the procedure, sec-
tions were washed 3 times with PBS for 5 min each
time.
Statistics
Pearson product-moment correlation coefficients (r) and
non-directional p values were determined to investigate
possible correspondences between aggrecan G1 degrad-
ation products and either patient age or disease
duration.
Results
Structural heterogeneity was analyzed in aggrecan iso-
lated from 34 individuals, including 11 males and 23 fe-
males, ranging in age from 46 to 89 years at the time of
total knee replacement for osteoarthritis (Table 1). The
aggrecan was routinely obtained from articular cartilage
lying midway between the osteoarthritic lesion and the
joint margin. Agarose gel electrophoresis showed size
variation in the aggrecan present in different individuals,
presumably due to different extents of proteolysis (Fig. 2).
However, there was no evidence for extensive
Table 2 Proportions of aggrecanase and MMP G1 degradation
products
Patient ID Aggrecanase G1a MMP G1a Ratio (G1-Agg/G1-MMP)
3 338 290 1.16
4 579 223 2.59
5 251 302 0.83
6 388 165 2.35
7 516 335 1.54
8 456 156 2.92
9 352 352 1.00
10 671 423 1.58
11 904 574 1.57
12 396 139 2.84
13 643 171 3.76
14 226 59.9 3.77
15 263 116 2.26
16 491 190 2.58
17 524 392 1.34
18 503 110 4.57
19 23.2 111 0.21
20 515 200 2.57
21 386 306 1.26
22 452 271 1.66
23 240 177 1.36
24 518 259 2.00
25 218 10.8 20.2
26 323 45.4 7.12
27 405 480 0.84
28 256 280 0.91
29 324 273 1.18
30 726 604 1.20
31 215 96.6 2.23
32 254 243 1.04
33 418 213 1.96
34 56.0 27.2 2.06
aPixel intensity of G1 bands determined by densitometry
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degradation producing small fragments of aggrecan
bearing only a few CS or KS chains in any individual.
SDS-PAGE analysis of samples treated with keratanase
and chondroitinase to remove glycosaminoglycan chains
showed fragments of multiple sizes possessing an aggre-
can G1 region, ranging from about 60 kDa to over
200 kDa (Fig. 3). Identical fragment sizes were observed
in all individuals studied, though the abundance of indi-
vidual fragments did vary. The two smallest fragments of
about 60 kDa (G1 MMP) and 75 kDa (G1 Agg) are indi-
cative of free aggrecan G1 regions resulting from
cleavage within the aggrecan IGD by matrix metallopro-
teinases or aggrecanases, respectively. This was con-
firmed by immunoblotting using anti-neoepitope
antibodies recognizing the new C-terminal amino acid
sequences generated by these proteinases (Fig. 3). It is
evident that in the majority of individuals the aggreca-
nase G1 cleavage product predominates (eg individual
M4), whereas in others the MMP product is of similar
abundance (eg individual M5) or in one case clearly pre-
dominates (individual M19; Table 2). These results sug-
gest that the same proteolytic mechanisms were
operating in all individuals, but that the contribution
from the different proteases involved did vary. No cor-
relation between the extent of aggrecanase or MMP
action was observed with either age of the individual
(r = −0.109 and −0.191, respectively, p > > 0.05) or dis-
ease duration (r = 0.049 and 0.246, respectively, p > 0.05)
for the group of patients studied. However, on separation
of the data for males and females, the abundance of
MMP-generated G1 appears to increase with disease dur-
ation in the males (r = 0.615, p = 0.044) (Tables 1 and 2).
When aggrecan from different sites within the same
joint was analyzed by SDS-PAGE, there was no variation
in the size range of the fragments observed, but there
was variation in the abundance of individual fragments
(Fig. 4). The most notable change was in cartilage adja-
cent to the OA lesion, where fragments larger than the
free G1 region were much less abundant than in more
remote areas, indicating more extensive degradation.
The use of antibodies recognizing different regions of
the aggrecan molecule, suggested that the majority of
the fragments bear a G1 region and range in size up to
that of the intact aggrecan. It appears that heterogeneity
is a result of proteolysis within the IGD, surrounding the
KS-rich domain, and within the CS2 domain. It also ap-
pears that the majority of fragments that no longer pos-
sess a G1 domain are lost from the tissue, possibly by
diffusion into the synovial fluid due to absence of inter-
action with HA.
To further confirm cleavage within the CS2 domain of
aggrecan in OA cartilage, a representative OA sample
was further examined by agarose gel electrophoresis fol-
lowing in vitro proteolytic degradation (Fig. 5). Neonatal
Fig. 2 Agarose gel electrophoresis of aggrecan from different
individuals. Proteoglycan from guanidine extracts of OA articular
cartilage were analyzed by electrophoresis on agarose gels.
Aggrecan was visualized by staining the gel with Toluidine blue.
Cartilage samples were obtained midway between the lesion and
the joint margin from the femoral condyles. Representative samples
from eight individuals (M3-M10) are shown. The migration position
of isolated chondroitin sulfate chains, indicated as CS, is included to
demark the migration position of the smallest possible proteolytic
cleavage product
Fig. 3 SDS-PAGE and immunoblotting of aggrecan from different
individuals. Proteoglycan from guanidine extracts of OA articular
cartilage, treated with keratanase and chondroitinase ABC, were
analyzed by electrophoresis on polyacrylamide gels, and the
fractionated proteoglycan then transferred to nitrocellulose
membranes. Aggrecan was visualized by immunoblotting using an
antibody recognizing the G1 region. Cartilage samples were
obtained midway between the lesion and the joint margin from the
femoral condyles and representative samples from eight individuals
(M3-M10) are shown. Molecular weights of reference proteins are
indicated at the left hand side of the blot. The migration positions
of G1 generated by MMP action (G1-MMP) or aggrecanase action
(G1-Agg) were determined using anti-neoepitope antibodies specific
for their C-terminal peptide sequences (αG1 MMP and αG1 Agg,
respectively). αG1MMP shows both terminal neoepitope and some
internal sequence recognition
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human aggrecan was used as a control representing
intact aggrecan. When the neonatal aggrecan was de-
graded by trypsin, two fragment sizes were produced,
the larger representing the CS1 domain, which is resist-
ant to trypsin cleavage, and the smaller representing
fragments from the KS-rich and CS2 domains [29].
ADAMTS5 gave a similar fragment pattern, though the
two fragment pools were of larger size. This results from
aggrecanases cleaving only within the IGD and CS2 do-
mains. MMP3 shows no extensive cleavage of the aggre-
can within its CS1 or CS2 domains. When the aggrecan
from the adult OA cartilage was degraded by trypsin,
both fragment pools were of smaller size than with the
neonatal aggrecan due to the smaller length of the CS
chains that are present in the adult [5]. However, the ra-
tio of the two pools was also different with fragments
representing the CS2 domain being less abundant than
those representing the CS1 domain. This supports prote-
olysis within the CS2 domain in the OA cartilage, which
would result in partial loss from the tissue. This conclu-
sion is reinforced by the ADAMTS5 cleavage pattern,
though it should be noted that the CS1-containing frag-
ments now appear as two components due to incom-
plete cleavage within the CS2 domain in the adult. As
with the neonatal aggrecan, MMP3 does not show ex-
tensive degradation of the adult aggrecan and is not
informative.
The identity of the CS1 domain following trypsin di-
gestion and analysis by agarose gel electrophoresis was
confirmed by immunoblotting. While most samples
showed the expected single band coincident with the
slower migrating Toluidine Blue staining product, essen-
tially no reaction was seen in the samples from individ-
uals M17 and M34 (Fig. 6). Failure of an anti-peptide
antibody to react with its intended epitope can indicate
that the sequence of the protein target differs from that
used for immunization, for example due to the presence
of non-synonymous SNPs. Consultation of the 1000 ge-
nomes database indicated that the region used for anti-
body production contains two known SNPs. While one
of these is very rare, the other occurs with nearly equal
Fig. 4 SDS-PAGE and immunoblotting of aggrecan with antibodies to different regions. Proteoglycan from guanidine extracts of OA articular
cartilage, treated with keratanase and chondroitinase ABC, was analyzed by electrophoresis on polyacrylamide gels, and the fractionated
proteoglycan then transferred to nitrocellulose membranes. Aggrecan was visualized by immunoblotting using antibodies recognizing the G1, G2,
CS1 or G3 regions. Cartilage samples were obtained adjacent to the lesion (L), midway between the lesion and the joint margin (M), and remote
from the lesion (R) from the femoral condyles. Representative samples from patient 1 are shown. Molecular weights of reference proteins are
indicated at the left hand side of the blot. Schematic diagrams depicting the core protein structure of aggrecan fragments of different sizes are
included at the right side of the blot
Fig. 5 Agarose gel electrophoresis of aggrecan treated with
different proteases. Proteoglycan from guanidine extracts of
neonatal cartilage and OA articular cartilage (M5) were analyzed by
electrophoresis on agarose gels following digestion with trypsin,
MMP3 or ADAMTS5. Aggrecan was visualized by staining the gel
with Toluidine blue. The OA cartilage samples were obtained
midway between the lesion and the joint margin from the femoral
condyle (M5). The migration position of isolated chondroitin sulfate
chains (CS) is also presented to indicate the migration position of
the small proteolytic fragments
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abundance to the reference sequence isoform. This nu-
cleotide substitution c.2789G > T located in the center of
the immunizing peptide replaces a serine residue with
an isoleucine, which represents a non-conservative
change in sidechain character. Sequencing of genomic
DNA showed that most of the individuals were hetero-
zygous at position 2789. However, the two individuals
that failed to react with the anti-CS1 antibody were
homozygous for the T (Ile) form (Fig. 6), which was not
used for antibody preparation.
Proteolysis was also studied by SDS-PAGE analysis of
the link protein that stabilizes the interaction of aggre-
can with HA. Different patterns of link protein cleavage
were observed depending on the extent of link protein
fragmentation. Three major link protein components
were evident (LP1, LP2 and LP3). LP1 and LP2 represent
the intact link protein and differ only in their degree of
N-linked glycosylation, whereas LP3 is generated by
MMP action [30]. In some individuals only these three
components were present, however, many individuals
also showed the presence of LP fragments of smaller
size, compatible with cleavage within the disulfide-
bonded A-loop. This region is not cleaved by MMPs or
aggrecanases, and therefore is indicative of an add-
itional proteolytic mechanism being operative in some
individuals. Representative examples of this variation
are shown in Fig. 7.
To determine whether MMPs and aggrecanases are
acting at the same sites within the cartilage, tissue close
to the lesion, but with an intact articular surface, was ex-
amined by Safranin O staining and immunohistochemis-
try (Fig. 8). Safranin O staining reveals the sites at which
proteoglycan loss is most abundant, and shows that loss
increases from the deep layers towards the articular sur-
face. The presence of aggrecan G1 domains also in-
creases towards the surface, and this correlates with the
presence of free G1 domains generated by aggrecanase
action (corresponding to reactivity to anti-G1Agg). In
contrast, MMP-derived G1 domains (corresponding to
reactivity to anti-G1MMP) appear more uniformly dis-
tributed throughout the cartilage depth. Thus the aggre-
can loss typifying the OA cartilage is more associated
with aggrecanase than MMP action.
Discussion
The current work demonstrates that MMPs and aggre-
canases are the major proteases involved in aggrecan
degradation in adult cartilage, with the aggrecanases be-
ing most associated with the increase in aggrecan loss
associated with OA. The extent of aggrecan cleavage
was highly variable between individuals, but was greatest
in areas of cartilage adjacent to sites of cartilage erosion
compared to sites more remote within the same joint.
The proportion of aggrecan cleavage attributable to
MMPs or aggrecanases was also variable, but aggreca-
nase action was usually predominant in late stage OA as
A
B
Fig. 6 Aggrecan samples from seven osteoarthritis patients were
digested exhaustively with trypsin then analyzed by agarose gel
electrophoresis. a Toluidine Blue staining, b immunostaining with an
anti-CS1 anti-peptide antibody. The patient identification numbers
are indicated above each lane, and the genotypes at position 2789
of the aggrecan cDNA are indicated below each lane
Fig. 7 SDS-PAGE and immunoblotting of link protein from different
individuals. Proteins from guanidine extracts of OA articular cartilage
were analyzed by electrophoresis on polyacrylamide gels, and the
fractionated proteins then transferred to nitrocellulose membranes.
The membrane was analyzed by immunoblotting using an antibody
recognizing link protein (αLP). Cartilage samples were obtained
adjacent to the lesion (L5 and L30). midway between the lesion and
the joint margin (M5 and M30), and remote from the lesion (R5 and
R30) from the femoral condyles and are shown for two representative
individuals. Molecular weights of reference proteins are indicated at
the left hand side of the blot. Schematic diagrams depicting the
structure of link protein components of different sizes are included at
the right side of the blot. LP1 and LP2 represent the intact link protein,
whereas LP3 and LP frag represent proteolytic cleavage products
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in no case was all the G1 product observed to be con-
verted into the MMP-generated form. Analysis of link
protein shows that in some individuals additional pro-
teolytic mechanisms must also be involved to some
extent.
There are several plausible mechanisms that could give
rise to the individual variation in proteolysis. First, the
duration of disease. Even if there is no variation in the
abundance of MMPs and aggrecanases produced within
the cartilage, a longer time of exposure will always result
in a relative increase in MMP-derived G1 regions, as the
MMP cleavage site within the IGD is closer to the G1
region than that of the aggrecanases [23]. Second, the
presence of joint inflammation. Synovitis will result in
cytokine-mediated production of both MMPs and aggre-
canases, which can diffuse through the synovial fluid
into the cartilage. However, at least in vitro the two
major inflammatory cytokines, interleukin 1 and tumor
necrosis factor α, stimulate the secretion of active aggre-
canases but latent MMPs [31]. While MMP activation
may not occur in vivo in all individuals, cytokine release
during synovitis will be associated with increased
aggrecanase-mediated aggrecan degradation in the more
superficial regions of the articular cartilage. Third, the
extent of joint loading. The incidence of OA is associ-
ated with obesity [32] which will result in increased
compressive loading of the cartilage. Increased compres-
sive loading has in turn been associated with increased
proteolysis, and at least in the case of the intervertebral
disc such compression-mediated proteolysis is associated
with MMP action [33]. Thus it is not surprising that
there is no unique mechanism responsible for cartilage
destruction in OA.
The lack of CS1 epitope recognition in some individuals
provides a strong caveat regarding the choice of peptide
sequences for antibody production, indicating that natur-
ally occurring polymorphisms need to be taken into ac-
count. SNPs are very common, particularly in outbred
organisms such as humans. For example, in the human
aggrecan cDNA sequence, encoding about 2400 amino
acid residues, over 500 SNPs generating missense variants
have been reported, of which 50 have minor allele frequen-
cies of greater than 0.1 (http://www.ncbi.nlm.nih.gov/SNP/
). These would not be considered when using database
cDNA sequences that are usually obtained from single in-
dividuals, and which may not be the most representative
of the general population. Therefore, when using anti-
bodies recognizing a single peptide sequence, such as anti-
peptide or monoclonal antibodies, it is essential to ensure
that the target sequence does not include sites of amino
acid variation. If this cannot be verified, negative results
obtained upon using the antibody must be treated with
caution. This is of particular concern when employing
commercial antibodies where the epitope recognized by
the antibody is often not disclosed or custom antibodies
that were prepared prior to the availability of the SNP
database. In addition, such single residue substitutions
may also modify susceptibility to proteolytic degradation
by rendering the protein sequence more (or less) predis-
posed to the selectivity of proteases present in the tissue.
Previous work relating to aggrecan degradation in OA
has centered on the composition of aggrecan fragments
that accumulate in patient synovial fluid [14–16, 34].
Using anti-neoepitope antibodies, fragments have been
assigned to be products of MMP or aggrecanase action.
It was concluded that MMPs are responsible for normal
aggrecan turnover whereas aggrecanases contribute to
its degradation under pathological conditions [15]. How-
ever, when studying aggrecan fragments in synovial fluid,
it is not possible to be sure whether degradation generat-
ing the fragments occurred within the cartilage or within
the synovial fluid itself due to proteases released by the
synovium. Our findings on the aggrecan components
retained in the cartilage matrix complement these
previous findings by showing only what is occurring
in the cartilage.
Link protein cleavage can also serve as a monitor of
protease action in cartilage in vivo [35]. Previous studies
Fig. 8 Histology and immunohistochemistry of cartilage. Full thickness articular cartilage was used to prepare frozen sections. Aggrecan in the
sections was visualized either by staining with Safranin O or by exposure to antibodies recognizing the G1 region (αG1) or the C-terminal
neoepitopes generated in the IGD by the action of MMPs (αG1 MMP) or aggrecanases (αG1 Agg). Control sections in which the primary antibody
was replaced by non-immune IgG were also prepared. Representative sections close to the lesion derived from patient 30 are shown. The scale
bar indicates 200 μm
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have demonstrated that MMPs are responsible for the
generation of LP3 from either LP1 or LP2 [30] and that
link protein is resistant to aggrecanase cleavage [19]. In
previous studies, the production of link protein frag-
ments has been limited to the action of free radicals or
the cysteine proteases cathepsin L, which can cleave
within the A-loop of the link protein [35]. Recent studies
have shown that cathepsin K can also cleave in this re-
gion (unpublished observation). This is of interest as ca-
thepsin K has also been implicated in collagen
degradation in arthritic cartilage [36], and could play a
more widespread role in extracellular matrix degradation.
Conclusions
For many years the development of protease inhibitors as
therapeutics to slow down or even prevent the cartilage
destruction associated with OA has been the goal of arth-
ritis research [37]. The present studies indicate that there
is no one protease, or a fixed combination of proteases, re-
sponsible for cartilage degradation in OA. Thus, rather
than targeting the individual proteases for OA therapy,
directing research to techniques that control global prote-
ase generation may be more productive [38].
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